Optimal biologics for juvenile idiopathic arthritis in an infection with SARS-CoV-2 &#945;-variant.

Adachi, Shunichi; Sonoda, Motoshi; Ishimura, Masataka; Eguchi, Katsuhide; Tanaka, Tamami; Motomura, Yoshitomo; Ohga, Shouichi

Optimal biologics for juvenile idiopathic arthritis in an infection with SARS-CoV-2 α-variant.

Adachi, Shunichi; Sonoda, Motoshi; Ishimura, Masataka; Eguchi, Katsuhide; Tanaka, Tamami; Motomura, Yoshitomo; Ohga, Shouichi.

Afiliação

Adachi S; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Sonoda M; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ishimura M; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Eguchi K; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tanaka T; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Motomura Y; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ohga S; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Pediatr Allergy Immunol ; 33(1): e13686, 2022 01.

Article em En | MEDLINE | ID: mdl-34741565

Assuntos

Artrite Juvenil; Produtos Biológicos; COVID-19; Anticorpos Monoclonais Humanizados; Artrite Juvenil/tratamento farmacológico; Produtos Biológicos/uso terapêutico; Criança; Feminino; Humanos; SARS-CoV-2

Palavras-chave

COVID-19; juvenile idiopathic arthritis; tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Juvenil / Produtos Biológicos / COVID-19 Limite: Child / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google